Targeting deltaFosB for treatment of dyskinesia
AssigneesRutgers, The State University of New Jersey, Emory University
InventorsMary M. Mouradian, Stella Papa, Jie Zhang, Goichi Beck
Life of this patent
Estimating the term…
Abstract
Compositions, non-viral vectors, recombinant viruses, and recombinant viral vectors for inhibiting ΔFosB expression or activity in a cell and for treating dyskinesia in a subject (e.g., a human patient having Parkinson's disease and Levodopa-induced dyskinesia) include a nucleic acid sequence encoding a shRNA specific for ΔFosB. Methods of using these compositions, non-viral vectors, recombinant viruses, and recombinant viral vectors are also described herein. These compositions, non-viral vectors, recombinant viruses, and recombinant viral vectors and methods of use provide novel therapies for dyskinesia based on the reduction of ΔFosB expression and/or activity.
Claims14
A recombinant viral vector comprising (a) a heterologous polynucleotide sequence comprising a nucleic acid sequence encoding at least one shRNA specific for ΔFosB, wherein the at least one shRNA has at least 90% or more sequence identity with the sequence of SEQ ID NO:
- 1 or at least 90% or more sequence identity with the sequence of SEQ ID NO:
- 2, and (b) inverted terminal repeat (ITR) sequences flanking the heterologous polynucleotide sequence.
Dependencies are inferred from the claim text.